Compare AstraZeneca plc (AZN) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Williams Companies Inc — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Williams Companies Inc trades at $75.9 (market cap $92.92B). The key difference: AstraZeneca plc is far larger — about 2.7× Williams Companies Inc's market cap, and Williams Companies Inc pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| AZN | WMB | |
|---|---|---|
Market Cap | $253.13B | $92.92B |
Sector | Health | Energy |
52-Week High | $209.48 | $79.40 |
52-Week Low | $137.44 | $56.51 |
Enterprise Value | $279.37B | $122.31B |
Dividend Yield | 1.92% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Williams Companies (WMB) trades at $74.46, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $11.95 billion in 2025 with a net income margin of 23.4%, and recent news highlights a $5.34 billion Blackstone-led investment to accelerate power projects. Valuation ratios include a P/E of 32.66 and P/B of 7.03, reflecting premium pricing relative to historical levels.
WMB presents a positive outlook with a consensus price target of $85.67, indicating 15% upside potential, supported by stable cash flows and strategic investments in energy infrastructure. Risks include exposure to natural gas price volatility and high debt levels, but the company's fee-based contracts and growth initiatives provide a buffer against market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
